Physician profile
Alan L Epstein
NPI 1346211844
$1,157,600.50
in general payments reported to CMS, 2019-2025
34 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335K · 2020: $142K · 2021: $140K · 2022: $185K · 2023: $156K · 2024: $151K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $271K · Consulting Fee: $43K · Travel and Lodging: $31K · Food and Beverage: $9,637 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $271,000.50 |
| Consulting Fee | $42,640.00 |
| Travel and Lodging | $31,495.54 |
| Food and Beverage | $9,637.14 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $198,915.06 | 2019-2024 | |
| Abbvie INC. | $179,106.09 | 2019-2025 | |
| Lilly USA, LLC | $163,762.30 | 2019-2024 | Taltz |
| Amgen INC. | $106,556.67 | 2019-2025 | Tavneos, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $97,142.48 | 2021-2025 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $69,703.21 | 2019-2025 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $62,710.85 | 2019 | |
| Janssen Biotech, INC. | $61,351.93 | 2019-2025 | Simponi Aria, Tremfya |
| Janssen Scientific Affairs, LLC | $57,867.49 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $38,672.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $30,327.83 | 2019-2023 | |
| United Rheumatology | $28,899.74 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $24,247.97 | 2019-2024 | Orencia |
| Sandoz INC. | $9,750.98 | 2019 | |
| Fresenius Kabi USA, LLC | $6,925.43 | 2023-2024 | Idacio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,643.15 | 2019 | |
| Ucb, INC. | $5,093.65 | 2019-2024 | Cimzia, Bimzelx |
| Sobi, INC | $2,809.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,231.52 | 2020-2025 | |
| Horizon Therapeutics Plc | $2,118.93 | 2019-2020 | |
| Invivyd INC | $2,012.50 | 2025 | Pemgarda |
| Eli Lilly and Company | $774.99 | 2020-2023 | Taltz |
| Aurinia Pharma U.S., INC. | $479.45 | 2021-2023 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $143.98 | 2019-2020 | |
| Genentech USA, INC. | $133.32 | 2019-2023 | Actemra, Rituxan |
| Depuy Synthes Sales INC. | $51.68 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $49.30 | 2019 | |
| Zimmer Biomet Holdings, INC. | $30.41 | 2022 | |
| Merck Sharp & Dohme LLC | $22.81 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $20.17 | 2021 | |
| Fidia Pharma USA INC. | $19.34 | 2023 | Hymovis |
| Medexus Pharma, INC. | $13.17 | 2019 | |
| Pacira Therapeutics, INC. | $12.05 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.